Showing results (1881-1890 of 5,275) with videos related to

Sort By:
Pageof 528
Oncology|January 1, 1986
Three alkaloids as selective destroyers of cancer cells in mice. Synergy with classic anticancer drugsM Beljanski, M S Beljanski
Oncology|January 1, 1986
Different sensitivity of two Walker 256 carcinoma lines to cyclophosphamide: correlation with drug distribution, biotransformation and macromolecule bindingM G Donelli, A Guaitani, L Torti, et al.
Oncology|January 1, 1989
The relation of ATP response in CaNT tumours after X-irradiation to varying tumour volumesD Szeinfeld
Oncology|April 15, 2015
Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with SorafenibMaria-Katharina Ganten, Max Schuessler, Thomas Bruckner, et al.
Oncology|July 27, 2020
Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase InhibitorsShinsuke Uchikawa, Tomokazu Kawaoka, Yuwa Ando, et al.
Oncology|January 1, 1988
High-dose dexamethasone and high-dose metoclopramide versus high-dose dexamethasone and sulpiride in the management of cisplatin-induced emesisE Rosenblatt, L M Lev, E Robinson
Oncology|September 20, 2002
Phase II trial of vinorelbine, cisplatin and continuous infusion of 5-fluorouracil followed by hyperfractionated radiotherapy in locally advanced head and neck cancerRoberto Orecchia, Barbara A Jereczek-Fossa, Gianpiero Catalano, et al.
Oncology|September 20, 2002
Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer (stage IIIb or IV) with a higher T stage (> T2). Technetium-99m methoxyisobutylisonitrile chest single photon emission computed tomography and P-glycoprotein express ionWu-Huei Hsu, Ruoh-Fang Yen, Chia-Hung Kao, et al.
Oncology|August 21, 2002
Neoadjuvant chemotherapy with sequential methotrexate and 5-fluorouracil scheduling, epirubicin and cisplatin for locally advanced bladder cancerTsutomu Nishiyama, Toshiki Tanikawa, Yoshihiko Tomita, et al.
Oncology|August 21, 2002
DNA aneuploidy in relation to the combination of analysis of estrogen receptor, progesterone receptor, p53 protein and epidermal growth factor receptor in 498 breast cancersShinichi Tsutsui, Shinji Ohno, Shigeru Murakami, et al.
Pageof 528